Eisai has completed the acquisition of AkaRx for $255 million, in a move which will give it sole worldwide rights to the US firm's thrombocytopenia drug AKR-501.
The transaction, first announced last month, was routed through the Japanese firm's US subsidiary, which now wholly owns New Jersey-based...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?